Simcere Pharmaceutical Group Limited Stock
Stocks
2096
HK0000658531
Pharmaceuticals
OTC Markets Traded|
Delayed
Hong Kong S.E.
23:51:32 2026-10-21 EDT
|
5-day change | 1st Jan Change | ||
| 10.54 HKD | -3.04% |
|
-2.68% | -11.95% |
| 10-19 | Roche Partners With China's Hansoh in Deal That Could Top $15 Billion -- Update | DJ |
| 10-19 | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 3.56B 27.92B 3.17B 2.94B 2.66B 5B 336B 5.06B 35.19B 13.81B 176B 13.35B 13.07B 562B | P/E 2026 * |
13.4x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 3.36B 26.37B 2.99B 2.77B 2.51B 4.73B 317B 4.78B 33.24B 13.04B 167B 12.61B 12.34B 531B | EV / Sales 2026 * |
2.23x | EV / Sales 2027 * | 1.95x |
| Free-Float |
33.7% | Yield 2026 * |
3.9% | Yield 2027 * | 4.42% |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 2096 | Delayed | |
OTC Markets
| SMHGF | Delayed | |
|
Tradegate
| S2P | Real-time | |
|
Deutsche Boerse AG
| S2P | Delayed | |
|
Börse Stuttgart
| S2P | Delayed | |
|
Boerse Muenchen
| S2P | Real-time |
| 1 day | -3.04% | ||
| 1 week | -2.68% | ||
| Current month | -11.05% | ||
| 1 month | -9.14% | ||
| 3 months | -20.87% | ||
| 6 months | -17.40% | ||
| Current year | -11.95% |
| 1 week | 10.4 |  | 11.29 |
| 1 month | 10.4 | | 11.89 |
| Current year | 9.07 | | 14.28 |
| 1 year | 9.07 | | 14.38 |
| 3 years | 4.94 | | 15.08 |
| 5 years | 4.94 | | 15.08 |
| 10 years | 4.94 | | 15.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jinsheng Ren
CEO | Chief Executive Officer | 63 | 2026-08-19 |
Yunshu Zhou
CEO | Chief Executive Officer | 54 | 2026-03-24 |
Yushan Wan
DFI | Director of Finance/CFO | 55 | 2019-11-18 |
| Director | Title | Age | Since |
|---|---|---|---|
Jinsheng Ren
CHM | Chairman | 63 | 2012-10-07 |
Yushan Wan
BRD | Director/Board Member | 55 | 2019-11-18 |
Renhong Tang
BRD | Director/Board Member | 46 | 2019-10-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/20/26 | Other | Chairperson | -3,000,000 | 0.1168% | ||
| 7/13/26 | Other | Founder | -47,000 | 0.0018% | ||
| 7/13/26 | Other | Director | -47,000 | 0.0018% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.04% | -2.68% | -17.85% | +65.20% | 3.58B | |
| -1.01% | +5.13% | +58.93% | +117.36% | 1,144B | |
| -0.61% | +1.52% | +34.34% | +68.48% | 625B | |
| -1.48% | +0.47% | +23.08% | +94.76% | 511B | |
| +0.54% | +5.69% | +39.60% | +64.02% | 377B | |
| +1.07% | +1.70% | +71.06% | +45.98% | 366B | |
| +0.30% | +3.44% | +21.35% | +49.62% | 291B | |
| -0.03% | +2.55% | +1.12% | +20.94% | 262B | |
| -0.14% | +2.87% | +45.56% | +57.22% | 237B | |
| -1.88% | +0.02% | +23.77% | +97.39% | 194B | |
| Average | -0.34% | +3.41% | +30.10% | +68.10% | 401.15B | |
| Weighted average by Cap. | +0.33% | +4.17% | +40.76% | +79.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.51B 11.84B 1.35B 1.25B 1.13B 2.12B 142B 2.15B 14.93B 5.86B 74.87B 5.66B 5.54B 239B | 1.76B 13.79B 1.57B 1.45B 1.31B 2.47B 166B 2.5B 17.38B 6.82B 87.16B 6.59B 6.45B 278B |
| Net income | 257M 2.01B 229M 212M 192M 361M 24.22B 365M 2.54B 996M 12.73B 963M 943M 40.57B | 303M 2.38B 270M 250M 227M 427M 28.64B 432M 3B 1.18B 15.05B 1.14B 1.11B 47.97B |
| Net Debt | -197M -1.55B -176M -163M -147M -278M -18.62B -281M -1.95B -766M -9.79B -740M -725M -31.19B | -140M -1.1B -125M -115M -104M -197M -13.19B -199M -1.38B -542M -6.93B -524M -513M -22.09B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-21 | HK$10.54 | -3.04% | 1,971,000 |
| 26-10-21 | HK$10.87 | -0.64% | 2,100,000 |
| 26-10-20 | HK$10.94 | -0.73% | 2,445,000 |
| 26-10-16 | HK$11.02 | +1.75% | 5,801,000 |
| 26-10-15 | HK$10.83 | -0.46% | 3,387,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- 2096 Stock
Select your edition
All financial news and data tailored to specific country editions
